Drug Trial Radar · NCT04124965
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
Last checked: Nov 20, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
71
Actual
Start
Oct 29, 2019
Primary completion
Sep 1, 2021
Study completion Sep 1, 2021
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Oct 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the MycarinGstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (MG).
Conditions
- Generalized Myasthenia Gravis
Interventions
RozanolixizumabDrug
Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From Baseline until End of Study (up to Week 60)
- Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Permanent Withdrawal of Study MedicationTime frame: From Baseline until End of Study (up to Week 60)
Locations
43 sites in 12 countries. Site status is shown where the registry gives one.
Mg0004 50081
Phoenix, Arizona
Mg0004 50072
Los Angeles, California
Mg0004 50088
Washington D.C., District of Columbia
Mg0004 50120
Miami, Florida
Mg0004 50073
Tampa, Florida
Mg0004 50114
Indianapolis, Indiana
Mg0004 50121
Lexington, Kentucky
Mg0004 50077
New York, New York
Mg0004 50090
Winston-Salem, North Carolina
Mg0004 50096
Philadelphia, Pennsylvania
Mg0004 50066
Montreal, Canada
Mg0004 50070
Québec, Canada
Mg0004 50069
Toronto, Canada
Mg0004 40125
Ostrava-Poruba, Czechia
Mg0004 40124
Prague, Czechia
Mg0004 40128
Aalborg, Denmark
Mg0004 40129
Bordeaux, France
Mg0004 40132
Nice, France
Mg0004 40133
Paris, France
Mg0004 40131
Strasbourg, France
Mg0004 40140
Göttingen, Germany
Mg0004 40078
Leipzig, Germany
Mg0004 40177
Münster, Germany
Mg0004 40144
Milan, Italy
Mg0004 40146
Pavia, Italy
Mg0004 40148
Roma, Italy
Mg0004 40150
Roma, Italy
Mg0004 20078
Hanamaki Shi, Japan
Mg0004 20079
Hiroshima, Japan
Mg0004 20077
Miyagi, Japan
Mg0004 20076
Shinjuku-Ku, Japan
Mg0004 20032
Suita, Japan
Mg0004 40155
Gdansk, Poland
Mg0004 40154
Lodz, Poland
Mg0004 40151
Lublin, Poland
Mg0004 20027
Moscow, Russia
Mg0004 20001
Saint Petersburg, Russia
Mg0004 20028
Saint Petersburg, Russia
Mg0004 20055
Saint Petersburg, Russia
Mg0004 40159
Barcelona, Spain
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.